The Briefing

Gemini 3.5 Flash, launched at Google I/O, outperforms the older Gemini 3.1 Pro on coding and agentic benchmarks while running 4× faster and costing 40% less — erasing the trade-off between speed and intelligence that defined the last model generation.

A federal jury dismissed all of Musk's claims against Sam Altman and OpenAI in under two hours, clearing the last major legal overhang on a company valued at $852B and tracking toward what could be one of the largest IPOs in history.

Roche is paying $750M upfront — up to $1.05B total — to absorb Boston-based PathAI, embedding its AISight digital pathology platform into Roche Diagnostics and positioning the Swiss giant to lead AI-powered companion diagnostic development at global scale.

The IEA's Global EV Outlook, released today, projects 23 million EV sales this year — nearly 1-in-3 new cars worldwide — with Southeast Asia doubling its share and Chinese exports hitting record highs, reshaping where the global auto industry's centre of gravity sits.

The modular AI infrastructure startup landed a $230M Series B co-led by BlackRock at a $2B valuation, and paired it with a Johnson Controls factory deal in Arizona — a bet that the next compute bottleneck is geography, not silicon.

A unanimous Oakland jury found Musk's claims against Sam Altman and OpenAI time-barred by the statute of limitations, clearing the path for OpenAI's IPO push. The merits of whether OpenAI 'stole a charity' were never adjudicated — Musk says he'll appeal.

Google's biggest keynote of the year kicks off today with expected launches of Gemini 3.5, a new personal AI agent reportedly called Remy, and Android XR smart glasses. If the glasses ship with a real date, Google officially enters the consumer wearables race against Meta.

Roche is buying PathAI — its five-year digital pathology partner — in a move to fully vertically integrate AI-driven companion diagnostics into its core business. Whoever controls the AI layer in pathology labs controls the data moat that drug approvals increasingly depend on.

The Suzhou-based biotech raised $50M today — backed by OrbiMed and TCG Crossover — to fund a phase 2b trial of AC-101 for ulcerative colitis in the U.S. market. A China-born asset moving into American trials is the clearest sign yet that China-to-West biopharma licensing is accelerating.

Tesla's latest FSD release is the first to merge its mainstream Spring 2026 software with the Full Self-Driving code branch, signaling a convergence of its consumer and autonomy stacks. Faster iteration cycles here are Tesla's most credible answer to Waymo's robotaxi momentum.

Google's I/O keynote on May 19 is expected to center on a major Gemini upgrade, confirmed Android XR glasses, and a new Googlebook laptop platform — but sources already peg the new model as GPT-5.5-class, not frontier, signaling Google must win on distribution, not benchmarks.

Roche acquires digital pathology startup PathAI ($750M upfront, $300M in milestones), internalizing five years of co-developed AI companion-diagnostic algorithms. The deal collapses tissue processing, AI biomarker scoring, and CDx development into one vertically integrated Roche offering — and will likely trigger follow-on consolidation among remaining independents like Paige and Proscia.

OpenAI is collapsing its fragmented desktop product line into a single agentic superapp, a direct admission that product sprawl cost it ground to Anthropic. With a potential IPO on the horizon, the company is betting a unified platform beats a catalogue — and that 900M ChatGPT users become the funnel for enterprise agentic workflows.

UCB acquires Candid Therapeutics for $2B upfront plus $200M in milestones, adding a clinical-stage T-cell engager platform to its immunology pipeline. A targeted bet on the next wave of autoimmune biologics, arriving just as deal volume in 2026 is substantially outpacing last year on cancer and autoimmune drug activity.

Ford's secretive Universal Electric Vehicle platform promises 20% fewer parts and 15% faster assembly than the Mach-E — designed to structurally cut the cost base that's been bleeding Model e for billions. If the manufacturing math holds, this is how Detroit closes the unit-economics gap with Tesla, not via software.

OpenAI launched a majority-owned consulting arm — backed by TPG, Goldman, McKinsey, and 16 others — to embed engineers inside enterprises. The model war is over; the implementation war has just begun.

Roche is paying $750M upfront to absorb its longtime partner PathAI into its Diagnostics division, targeting AI-automated cancer diagnosis at global scale. This cements AI pathology as a must-have, not a nice-to-have.

Novo's end-to-end OpenAI integration — spanning drug discovery, manufacturing, and commercial ops — signals that pharma's AI moment is no longer pilot-stage. It's a direct strike at Lilly as both race to out-innovate in obesity and diabetes.

With FY26 revenue down 21% and EBIT margin collapsing to 0.7%, JLR is slashing costs and extending ICE model lifespans in the US. It's the starkest proof yet that Trump's 25% auto tariffs are forcing a real strategic pivot, not just a talking point.

The Cambridge biotech's Series B will fund in vivo immune programming — effectively rewriting immune cells inside patients without ex vivo manufacturing. If it works, it obliterates one of cell therapy's biggest cost and scale bottlenecks.

OpenAI's new Deployment Company embeds Forward Deployed Engineers inside client organizations, backed by TPG, Goldman, SoftBank, and 16 others. This isn't a product launch — it's OpenAI declaring war on Accenture and Palantir for the enterprise integration stack.

Roche is acquiring Boston-based PathAI, converting a five-year partnership into full ownership of its AI-powered digital pathology and companion diagnostics platform. Whoever owns the tissue-analysis algorithm owns the oncology trial pipeline.

Rivian opened the R2's public configurator a month ahead of its own June guidance, with the Performance trim priced at $57,990 — $890 below Tesla's Model Y Performance. The make-or-break volume vehicle's production ramp is now officially live.

Novo is deploying OpenAI across drug discovery, clinical trials, manufacturing, and commercial ops — with full rollout by end of 2026. The deal is a direct response to Eli Lilly's AI lead and signals that GLP-1 leaders are now competing on model access as much as molecule.

Anduril raised $5B from Thrive Capital and a16z at a valuation cementing it as the undisputed capital leader in defense tech, as 2025 revenue doubled to $2.2B. The round redefines what a 'startup' looks like when the customer is the Pentagon.

Sequoia, Dragoneer, Greenoaks, and Altimeter are co-leading a round that would make Anthropic more valuable than OpenAI on paper — a staggering re-rate driven by $44B in annualized revenue and Claude Code's enterprise dominance.

Roche's acquisition of PathAI locks AI-powered digital pathology into a global diagnostics behemoth, accelerating the shift from manual slide-reading to automated biomarker discovery — and setting a template for every mid-cap AI diagnostics startup watching from the sidelines.

After 14 years and ~750,000 units sold, Tesla has ended production of its founding flagship vehicles and is repurposing the factory line for Optimus humanoid robots — a blunt signal that Musk is betting the company's future on robotics, not cars.

Q1 2026 delivered just 216,000 EVs in the U.S., resetting the market to late-2022 levels after the federal tax credit expiry killed demand. Carmakers are now scrambling to find where the new floor is without government subsidy.

Novo's enterprise-wide OpenAI deal — spanning R&D, manufacturing, supply chain, and commercial ops — is the clearest signal yet that biopharma incumbents are treating AI as core infrastructure, not a pilot, in a race against Eli Lilly for the $100B+ obesity market.

Washington and Beijing agreed on best-practice guardrails to keep frontier models out of nonstate hands. Treasury's framing — leverage comes from the lead — signals AI is now core diplomatic currency.

The Nitrogen gang claims 8TB stolen, including project files tied to Apple and Nvidia. A single contract manufacturer is a chokepoint for the entire hardware industry — and attackers know it.

Strong AI infrastructure orders sent Cisco up 14% — its best day in two decades — and dragged the Dow back over 50,000. Hardware names are riding the AI capex wave that once flattered only the model builders.

Culper Research disclosed a Nvidia short over China-exposure risk as bears build a thesis around overhyped AI names. When skeptics start naming the index leader, froth is the real story.

Roche's definitive deal for PathAI doubles down on AI-driven pathology. Pharma is buying the algorithms that read the slides — owning diagnosis, not just the drug, is the new vertical play.

Expiring enhanced ACA tax credits, tighter prior-auth rules, and new state mandates are converging on payers. Roughly 450,000 lawfully present immigrants lose Essential Plan coverage in July.

Palo Alto Networks says enterprises have a narrow three-to-five-month window before models like Anthropic's Mythos make zero-day exploitation routine. Defense budgets built for last year's threat model are already obsolete.

Cisco blew past guidance on surging AI infrastructure orders while trimming under 5% of staff. The split screen is the story: AI demand is real, but it reshapes headcount even at the winners.

Google is in advanced discussions with SpaceX to launch AI compute into orbit, with SpaceX pitching space as the lowest-cost option. Power and cooling constraints on Earth are now pushing infrastructure off-planet.

The European Commission cleared Hympavzi for patients 12+ with inhibitors — a traditionally hard-to-treat group. It widens Pfizer's beachhead in a hemophilia market increasingly contested by gene therapies.

Governor Newsom unveiled a billion-dollar rebate for electric medium- and heavy-duty trucks as Washington retreats from clean-vehicle policy. States are becoming the real industrial-policy battleground for EVs.

Anduril's mega-round reinforces defense as the category VCs can't get enough of. The line between Silicon Valley and the Pentagon keeps blurring — and the capital following it is enormous.

South Korea's Kospi sank as much as 5.1% after a top policy adviser floated a 'citizen's dividend' funded by AI and chip profits. Samsung and SK Hynix led the rout before officials walked it back.

Google unveiled deep Gemini integration across Android 17 plus a new 'Googlebook' laptop platform — landing weeks ahead of Apple's expected Siri overhaul. The mobile AI assistant war is now a timing game.

Slumping AI stocks and rising oil prices halted Wall Street's record-breaking streak. The Korea scare exposed how tightly global markets are now wired to a handful of AI names.

VSE Corp is acquiring Precision Aviation Group from GenNx360 for $2B, doubling down on aftermarket aviation parts and services. Aerospace MRO consolidation keeps drawing private-equity exits.

A bipartisan bill from Reps. Moolenaar and Dingell would lock in restrictions on Chinese automakers and connected-vehicle tech, citing security and supply-chain risk. Decoupling in autos is hardening into law.

Google's Threat Intelligence Group says it disrupted hackers using an AI model to weaponize a zero-day and bypass two-factor auth — likely heading off a mass exploitation event. Offensive AI just went operational.

VoltaGrid formalized its $1B raise from Blackstone and Halliburton and is buying supplier Propell to scale power-generation capacity. Behind-the-meter generation is becoming its own AI-era asset class.

UPMC signed a definitive deal to take ownership of Ohio's Trinity Health System from CommonSpirit. Regional provider consolidation keeps grinding forward as standalone systems struggle to stay solvent.

iOS 26.5 brings end-to-end encryption for RCS messages between iPhone and Android — finally closing the cross-platform security gap. A quiet but overdue interoperability win.

Samsung, Hyundai and LG are backing Config, a startup positioning itself as a neutral supplier of robot training data. As robotics moves from demos to factories, the data layer becomes the choke point.

Alphabet momentarily passed Nvidia as the world's most valuable company in after-hours trading, up ~160% in a year. Owning the full AI stack — chips, models, cloud, distribution — is now the winning hand.

Blackstone and Halliburton are pouring $1B into VoltaGrid, a Houston firm building gas microgrids for data centers — valuing it above $10B. The AI race is now constrained by power, not silicon.

76% of organizations now have a chief AI officer, up from 26% a year ago. The C-suite is restructuring around AI faster than it did for the internet — a signal of how deep the shift runs.

The FDA opened a call for input on formally repurposing existing drugs for new conditions where data exists but commercial incentive doesn't. A pragmatic fix for orphaned medical needs.

Meta, Amazon, Microsoft and Alphabet have collectively signaled roughly $725B in 2026 capital spending — nearly all of it data centers, chips and AI models. The infrastructure arms race has no ceiling in sight.

With fresh deals for up to $3.2B in Corning and $2.1B in IREN, Nvidia's 2026 equity bets now top $40B. It's no longer just selling GPUs — it's underwriting the entire stack that buys them.

A draft executive order would force frontier models through pre-release red-teaming and disclosure, triggered by Anthropic's vulnerability-hunting Mythos. The hands-off era is ending — the question is who runs the gate.

China's chip fund and Tencent are circling DeepSeek's debut round, with the valuation jumping from $20B to $45B in weeks after its V4 model. Open-weight challengers are now priced like frontier labs.

After a 14-year run, Tesla built its final Model S and Model X at Fremont. The cars that proved EVs could be desirable are retired — Tesla is all-in on volume models and the robotaxi bet now.

Pfizer's BCMA-CD3 bispecific hit topline goals in the Phase 3 MagnetisMM-5 trial in earlier-line relapsed multiple myeloma. A push to move bispecifics out of last-resort use and into the standard sequence.

The new default ChatGPT model cuts hallucinations 50%+ in high-stakes cases and pulls context from past chats, files, and Gmail. The race has shifted from raw capability to reliability and memory.

Architect Capital buys 16% of OnlyFans parent Fenix for $535M, weeks after founder Leonid Radvinsky's death. A $7.2B gross-revenue creator engine quietly priced — succession, not strategy, drove the timing.

Broadcom will only finance the first phase of OpenAI's custom silicon if Microsoft commits to buy 40% of the chips — and Microsoft prefers generic designs. The vertical-integration dream is colliding with who pays.

Zuckerberg cast Meta's 8,000 job cuts as a cost offset against $115-135B in AI infrastructure spend, with another 6,000 open roles canceled. Headcount is now the variable that flexes to fund compute.

The FDA broadened argenx's VYVGART to all serotypes of generalized myasthenia gravis and granted its seventh National Priority Voucher. The voucher pilot is quietly becoming a real lever on review timelines.

A new InfluenceMap analysis ties roughly $70B in industry EV writedowns to automakers' own flip-flopping lobbying, which manufactured the regulatory chaos they now blame. Self-inflicted, while China kept building.

Roche will pay $750M upfront, up to $1.05B total, for digital pathology startup PathAI. Pharma is no longer dabbling in AI dx — it is buying the algorithm pipeline outright to feed companion diagnostics.

Anthropic grabs 300+ MW and 220,000 GPUs from SpaceX's Memphis data center, instantly doubling Claude Code limits. Compute scarcity is now the binding constraint on AI growth — and it gets bought in bulk.

OpenAI spun up a unit that embeds Forward Deployed Engineers inside customers to build around its models. The frontier labs are realizing the moat isn't the model — it's getting enterprises to actually ship with it.

Italy's Angelini Pharma will buy rare-disease firm Catalyst for $31.50/share, its entry into the US market. Mid-cap pharma keeps using M&A to buy commercial scale rather than build it.

The FDA is soliciting input on approving new uses for old drugs where science supports it but commercial incentives don't. A pragmatic fix for the gaps the market won't fund — metabolic, neuro, rare disease.

Google shut down its experimental AI browser agent, folding the tech into Gemini Agent and AI Mode. The standalone agent era is collapsing — capability is being absorbed into the assistants people already use.

The all-cash deal adds roughly $1.1B in annual sales of mission-critical instrumentation. Industrial consolidators are using strong balance sheets to scoop up niche, high-margin assets.

Q1 revenue grew 14.5% to $13.2B with an EPS beat, lifting shares 6%. Ride-hailing and delivery demand stays resilient even as the macro picture wobbles.

Fiscal Q2 EPS of $1.57 beat estimates on streaming and parks strength, sending shares up nearly 8%. The turnaround story is now a margins story.

Novo Nordisk raised guidance after its first oral weight-loss pill logged 2 million prescriptions out of the gate. The obesity market's next phase is convenience, and the race just reset.

With two-thirds of results in, 84% of S&P 500 companies have beaten estimates versus a 78% five-year average. Corporate America is absorbing the macro noise better than the headlines suggest.

Q1 revenue hit $10.3B with data center up 57% YoY on EPYC and Instinct GPU ramps. AMD is proving the AI compute boom has more than one credible winner.

Roughly 700 jobs gone as Coinbase kills 'pure manager' roles for AI-native pods and player-coaches. Whether it's real automation or AI-washing, the org chart is being rewritten.

The model claims 52.5% fewer hallucinated claims on high-stakes prompts in medicine, law and finance. Reliability, not raw capability, is now the battleground for default ChatGPT.

Q1 deliveries fell 4.4% yet revenue rose to 1.85B euros on richer mix and personalization, with full-year guidance reaffirmed. Scarcity plus customization remains the strongest moat in autos.

William Blair will acquire boutique advisory Inner Circle Sports, doubling down on the global sports, media and entertainment dealmaking wave. M&A advisors are buying their own pipeline.

Annualized revenue reportedly jumped from $9B toward $30B+ in a single quarter. If it holds, it reframes the frontier-lab economics debate: usage, not hype, is now the constraint.

Q1 revenue rose 85% to $1.63B with U.S. commercial up 104%, and management raised full-year guidance to 71% growth. The AI-platform thesis is converting into hard numbers.

New deals with Corning ($3.2B) and IREN ($2.1B) push optical-connectivity and compute capacity for AI factory buildouts. NVIDIA is increasingly investing in its own demand.

CareDx will acquire precision-oncology diagnostics firm Naveris for $160M upfront plus $100M in milestones. Transplant-testing leaders are pushing into the larger cancer-monitoring market.

Treasury Secretary Bessent says banks and tech firms are hardening defenses against AI-enabled cyber threats. The worry: attackers automating phishing and vulnerability discovery faster than defenders can patch.

First major US airline collapse in 25 years. 17,000 jobs gone, millions stranded after a Trump-administration bailout fell apart amid creditor opposition and an Iran-driven jet fuel spike. The Big Four are already capping rebooking fares.

Greg Abel slams the door on conglomerate-disassembly speculation at his debut Berkshire annual meeting. Theme — 'The Legacy Continues.' Translation: don't expect Buffett's playbook to change anytime soon.

India's biggest pharma deal ever vaults Sun into top-tier global women's health and generics. Signals two things: capital is flowing eastward, and Big Pharma spinouts are now prime acquisition targets.

Eli Lilly snaps up Ajax Therapeutics and its Type II JAK2 inhibitor, doubling down on hematology beyond the GLP-1 franchise. A diversification bet as Mounjaro and Zepbound competition intensifies.

Google's biggest model of the year — 2M-token context window working natively across text, image, audio, and video with no transcription step. The context-race just lapped the field again.

Quad-motor, 1,000+ hp, sub-2.5-second 0-60. Ferrari's first EV ends the last serious holdout in luxury performance. Heritage brands no longer have an exit ramp from electrification.

Mercedes, BMW, and VW absorb the blow. Section 232 invoked over alleged trade-deal noncompliance, a fresh tariff shock for a global auto industry already grinding through supply-chain whiplash and softening demand.

Masayoshi Son bundles ABB Robotics with AI-data-center ambitions into a pre-revenue spinout chasing a $100B valuation. The bet: autonomous robots will physically build the data centers powering frontier AI.

AWS, Google, Microsoft, Nvidia, OpenAI, SpaceX, Reflection, and Oracle won approval to deploy AI on DoD classified networks. Anthropic, already running there, was conspicuously left off, signaling a deepening Washington rift.

Meta lifted 2026 capex guidance to $125-145B and shares dropped 6% as Wall Street balked. Combined hyperscaler AI infrastructure spend now eclipses most national defense budgets, with no clear ROI horizon yet visible.

Ligand snaps up XOMA's royalty pure-play to consolidate a tightening sub-segment. Latest signal in a Q1 2026 biopharma M&A wave already topping $15.6B as patent-cliff anxiety pushes Big Pharma into aggressive bolt-ons.

Revenue climbed 17% to north of $95B with iPhone sales jumping 22%; June-quarter guide of 14-17% growth. The supercycle thesis just moved from hopeful narrative to balance-sheet reality.

Alphabet and Amazon posted clear AI revenue traction in Q1 while Meta trailed despite matching capex. Capital intensity is now separating the cloud-haves from the consumer-only-haves.

Iran-war fuel costs may liquidate Spirit within days, mid-bankruptcy. The ULCC model breaks first when input costs run faster than fare hikes can chase them.

Even on $1.7B Q1 profit and 5% revenue growth, Cigna will exit the ACA marketplaces after 2026, joining Aetna. The individual market is in structural decline, not a cycle.

India's Sun Pharma will buy Organon for $11.75B, anchoring a U.S. women's-health franchise. Cross-border specialty consolidation is back as patent cliffs squeeze growth.

Alphabet popped 9% on a Q1 beat while Meta and Microsoft slid 9% and 5% as investors balked at ballooning AI capex. The market is finally separating compute spenders who monetize from those still promising.

GPT-5.5 and Codex now run on Amazon Bedrock, a previously unthinkable detente. The Microsoft-only era is officially over, and Bedrock is positioning as the default multi-model enterprise stack.

Italy's Chiesi Group is buying KalVista Pharmaceuticals at $27 per share, sending the stock up 39%. Specialty rare-disease assets keep clearing at premiums while US big pharma sits on its hands.

India's Sun Pharma is acquiring US women's-health spinout Organon in an $11.75B deal. A non-Western buyer taking out a US-listed pharma at this scale signals a new global M&A pattern worth tracking.

CAT beat estimates and raised its annual revenue outlook, sending shares up 10% and the Dow up 730 points. The global-economy bellwether says infrastructure and energy demand remain very real.

Ford's Model e is on track to lose $4.0 to $4.5B in 2026, but Farley is doubling down on a sub-$30K electric pickup for 2027. The entire Detroit EV thesis hinges on this single SKU landing.

Microsoft, Alphabet, Meta, and Amazon all report after the bell tonight — investors will judge whether AI capex is showing operating leverage or just inflating the bill.

India's largest drugmaker pays a 103% premium for Organon's women's health and biosimilars portfolio, vaulting Sun into the global top 25 and the seventh-largest biosimilar player.

Canada and Germany back the transatlantic combination as Europe's answer to OpenAI and Anthropic — Schwarz Group anchors with a $600M Series E to fund the regulated-enterprise pitch.

PIONEER TEENS phase 3 superiority on HbA1c in 10–17 year olds opens a pediatric type 2 diabetes franchise and previews a 2H26 label-expansion filing for the oral GLP-1 form.

EVs held 5.8% of US new-vehicle sales in Q1, flat with Q4 and well off Q3 2025's 10.6% peak — the post-incentive shakeout has reached a floor, not a recovery.

Beijing ordered Meta to unwind its acquisition of AI agent startup Manus, citing national security. The problem: Meta already integrated the tech. This is China weaponizing retroactive deal reviews as geopolitical leverage.

India's largest drugmaker goes all-in on women's health and biosimilars, vaulting into the global top 25. The bet: $9B+ in new debt for a company spun off from Merck just five years ago.

OpenAI now generates $2B monthly and closed a $122B round at an $852B valuation. A 2026 filing targeting $1T would be the largest IPO ever — while the company still projects $14B in annual losses.

The Cobra Jet 2200 just became the quickest EV on the planet at the NHRA 4-Wide Nationals — 221 mph, twin motors, 2,200 HP, and a patented clutchless five-speed. Ford proving electrification and drag racing aren't mutually exclusive.

Idvynso (doravirine/islatravir) was approved a week early, giving virologically suppressed adults a new simplified regimen. Islatravir's rocky history makes this a redemption arc for Merck's HIV pipeline.

BYD's European sales surged 270% last year with 1M vehicles sold outside China, targeting 1.5M in 2026. The Seal 08 flagship promises 1,000km range and 400km in five-minute charging. Western OEMs are running out of runway.

GPT-5.5 rolls out across ChatGPT tiers tuned for multi-step coding, research, and software operation — OpenAI is leaning hard into agentic workflows as the differentiator, not raw IQ.

Apple folded hardware engineering and hardware technologies into one org under chip chief Johny Srouji as John Ternus transitions to CEO — silicon, devices, and AI features now ship as one team.

Tesla cleared Q1 earnings on $22.4B revenue while capex leapt 67% to $2.49B — the company is openly pivoting investment toward humanoid robots and robotaxi while the EV core stagnates.

Three companies got National Priority Vouchers for psilocybin (depression) and methylone (PTSD) — the agency just put psychedelics on a regulatory glide path that could reshape mental health pharma.

After two years of failed talks, Lehigh Valley Health Network — now part of Jefferson — exited UnitedHealthcare's commercial network, the latest sign of escalating provider-payer brinkmanship.

Google rolled out a stack of agent-building tools to court enterprises away from OpenAI and Anthropic, betting that distribution through GCP plus its own silicon stack beats raw model performance.

Tesla is pouring more than $25B into self-driving, Optimus, and robotaxi this year — nearly 3x last year's spend. The company is now an AI infrastructure bet wrapped in a car company.

Otarmeni won accelerated approval as a one-shot gene therapy for inherited hearing loss — opening a new modality for sensory disorders and a template for AAV-delivered cures.

Rivian moved 10,365 EVs in Q1 — beating four legacy automakers — while Ford's EV sales collapsed 70%. The R2 hasn't even launched yet. Legacy OEMs are losing the EV race they swore they'd win.

The FDA unveiled a plan to accelerate development of psychedelic treatments for serious mental illness — a major regulatory shift that could unlock a wave of MDMA, psilocybin, and ketamine-derived programs.

DeepSeek open-sourced V4-Pro and V4-Flash with a native 1M-token window and Hybrid Attention Architecture, beating every open model on math and code while undercutting US frontier pricing.

Related Digital and Blackstone landed $16B for the Saline Township Oracle build powering OpenAI workloads, with PIMCO anchoring $10B of the BofA-led bond stack — a tangible marker of the AI infra capital cycle hitting full bore.

Zuckerberg told staff Meta will eliminate 10% of its workforce starting May 20 and scrap 6,000 open roles, the bluntest sign yet that hyperscaler capex ($115B-$135B in 2026) is being funded directly out of headcount.

Tesla beat Q1 EPS but warned of negative free cash flow the rest of 2026 as it pours capital into FSD, robots, and an Austin chip fab. Robotaxi miles nearly doubled QoQ — but Musk concedes meaningful revenue won't arrive before 2027.

Following a Trump executive order, the FDA handed Compass Pathways, Transcend, and Usona priority vouchers that could compress reviews to 1-2 months. A structural shift for mental-health pipelines — and a windfall signal for psychedelic biotechs.

Upgraded coding, computer-use, and deep-research capabilities land for Plus, Pro, and Enterprise tiers. The compressed release cadence signals OpenAI is pricing speed over polish as the capability race intensifies.

EPS of $0.29 blew past the $0.02 consensus on $13.58B revenue, sending shares up 22% after-hours. The turnaround narrative is finally finding traction — AI-driven business beat guidance for a sixth straight quarter.

Roughly 8,000 layoffs plus 6,000 unfilled roles, as capex guidance hits $115-135B — nearly double last year. Zuckerberg is making clear: fewer people, more GPUs, no apologies.

Musk conceded on the Q1 call that the current system isn't ready for mass deployment and millions of older Teslas will need new computers and cameras to ever reach full autonomy. The robotaxi timeline keeps slipping.

Revenue of $111.7B topped estimates and the insurer finally looks to have its medical-cost problem in hand. Shares jumped 8% — a signal that the managed-care bleeding from GLP-1s and post-pandemic demand may be stabilizing.

12M lost Zepbound coverage and 12M lost Wegovy coverage in the last year, and 88% of the remaining covered population faces prior-auth or BMI gates. The payer backlash against obesity drugs is reshaping the whole category.

Tesla topped EPS estimates but missed on revenue, then guided capex $5B above prior plan. The market is now being asked to fund Optimus and robotaxis before either earns a dollar.

Google folded Vertex AI into a Gemini Enterprise Agent Platform, shipped Workspace Studio, 200+ models (including Claude), and put A2A v1.0 in production. The agent wars just got a serious third front.

Anthropic committed to multi-gigawatt Alphabet/Broadcom TPUs starting 2027 plus 5GW from Amazon. Frontier AI has become a power-and-fab arms race, not just a software one.

UNH posted $7.23 EPS on $111.7B in revenue, lifted full-year EPS guide above $18.25, and authorized $2B in buybacks. The managed care narrative is flipping from crisis to comeback.

Google signed a multibillion-dollar expansion with Thinking Machines Lab for GB300-backed compute. Hyperscalers increasingly see frontier labs not as threats but as anchor customers for their silicon.

ChatGPT Images 2.0 launched with gpt-image-2 — it searches the web, self-checks outputs, and renders coherent slide decks, diagrams, and UI mockups. Image generation just graduated from rendering tool to visual thought partner.

Google Cloud Next 2026 kicks off in Vegas today, with a split between dedicated training and inference TPUs expected. A direct run at Nvidia's margin now that inference is the dominant AI compute workload.

Tesla reports after the bell having missed Q1 deliveries by 7,600 and produced 50K more cars than it sold. The robotaxi and Optimus narrative now has to carry a stock that auto demand alone can't.

Meta's new Model Capability Initiative captures clicks, keystrokes, and screenshots from US employees to train computer-use agents. A blunt admission that public web data no longer cuts it for the agent race.

Apple restructured hardware engineering into five groups — engineering, silicon, advanced tech, platform architecture, and project management — under Srouji. A bet that AI product velocity now hinges on tighter chip-device coordination.

The biggest leadership change in Silicon Valley in a decade. Ternus, Apple's hardware chief since the M1 era, takes the helm Sept 1 — signaling the company's next act is physical products and spatial computing, not services.

A massive global study confirms the AI haves-and-have-nots divide is widening fast. The top quintile generates 7.2x more AI-driven gains and is automating decisions at nearly 3x the rate of peers.

Microsoft discovered it was dramatically undercounting tokens from newer models and is now overhauling Copilot economics — removing Opus from the $10 plan and shifting toward pay-per-token. The flat-rate AI era is ending.

Wall Street expects $0.37 EPS on $22.7B revenue, but the real question is the $20B+ capex bill that doesn't even include Terafab. Deliveries missed consensus by 7,600 units and energy storage fell well short.

Biopharma companies raised $1.7B in Q1 IPOs — the most in five years — powered by 19 billion-dollar M&A deals recycling capital back into the ecosystem. The window is open but highly selective: no preclinical companies need apply.

The bladder cancer regimen showed a 47% recurrence risk reduction — this expansion beyond cisplatin-ineligible patients could reset the perioperative standard of care and cement Merck's post-LOE oncology franchise.

An 800V architecture, 330 kW charging, and a 94 kWh pack put the C-Class electric on par with BMW's Neue Klasse. Mercedes is finally done treating EVs as a separate product line.

The deal doubles a January compute pact and hands OpenAI warrants tied to spend — a clear signal that chip diversification away from Nvidia is now strategic, not experimental.

Active users cratered below 500K while the app burned $15M daily in compute. A rare public retrenchment for OpenAI — and a warning that consumer AI video isn't yet a standalone product.

The sharp upward revision looks politically motivated ahead of midterms, but it also hands UNH, Humana, and Elevance a cash-flow reprieve after a brutal year of MLR pressure.

IRGC gunboats hit three commercial vessels Saturday, slamming the strait shut again over the US blockade. One-fifth of global oil transits this chokepoint — expect another supply shock and $100+ crude.

New study of 1,200+ execs shows AI leaders generate 7.2x more gains than average competitors — and they're focused on revenue growth, not just cost cuts. The gap between AI haves and have-nots is widening fast.

Annualized revenue crossed $25B in February — 4x year-over-year. After closing a record $122B round at $852B valuation, an H2 filing could make this the largest public offering in history.

Third acquisition in two months for Gilead — this time a Munich-based ADC startup with two clinical-stage cancer assets. Antibody-drug conjugates are the new battleground in oncology M&A.

Anthropic's new flagship hits 87.6% on SWE-bench and 94.2% on GPQA with 3.3x sharper vision — but still trails its own unreleased Mythos model. The AI arms race is now Anthropic vs. Anthropic.

Amazon is acquiring satellite operator Globalstar at $90/share to supercharge its LEO internet play. A direct-to-device service is planned for 2028 — Musk's Starlink monopoly has an expiration date.

Spiegel calls it a 'crucible moment' — Snap is axing 1,000 jobs while AI generates two-thirds of new code. Stock jumped 11%. This is the clearest signal yet of AI-driven headcount compression at scale.

Novo is deploying OpenAI across R&D, manufacturing, and supply chain with full integration by year-end. It's a bet that AI can help claw back market share from Lilly in the $100B+ obesity drug race.

Google shipped native E2EE for Gmail on Android and iOS — no extra apps needed. Enterprise users can now send encrypted mail to anyone, finally making encrypted email frictionless.

HSBC and a Standard Chartered-led consortium won Hong Kong's inaugural stablecoin licenses from 36 applicants. HSBC plans to put it in PayMe — stablecoins are going mainstream retail.

Gilead's ADC shopping spree continues with a $5B Tubulis acquisition — its third buy since February after Arcellx ($7.8B) and Ouro ($2.2B). Oncology M&A is white-hot.

TSMC revenue jumped 35% to a new record on relentless AI chip orders. The infrastructure buildout behind every foundation model is nowhere near peaking.

GPT-5 Turbo can now run Python and JavaScript natively within responses. Priced at $5/M input tokens, directly competing with Claude's tool-use capabilities.

CVS is splitting Aetna into commercial, government, and specialty segments with separate P&Ls. The move signals potential for future divestitures.

Framework's modular laptop earns top recommendation for its user-swappable GPU, RAM, and storage — a direct challenge to Apple's soldered-component approach.

Google closes its $32B Wiz acquisition after a year of regulatory review. The deal vaults Google Cloud into the #1 position in cloud-native security.

The partnership bundles Azure AI with Epic's clinical documentation tools, targeting 200 health systems by year-end. Cerner customers are notably excluded.

Rivian turned its first profit driven by 150K R2 reservations and improved manufacturing efficiency. Stock surged 18% after-hours.